Nastech Finalizes Plans For RNAi Subsidiary To Focus On Phase II Inhaled Drug Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
Restructuring includes spinning out RNAi business, reducing 30 percent of work force to conserve cash.